Jonathan Miller
Stock Analyst at Evercore ISI Group
(0.47)
# 4,492
Out of 5,182 analysts
10
Total ratings
33.33%
Success rate
-17.18%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Miller
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Outperform | $33 → $48 | $28.56 | +68.07% | 1 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $11 → $13 | $2.13 | +510.33% | 1 | Mar 9, 2026 | |
| AVIR Atea Pharmaceuticals | Maintains: Outperform | $6 → $10 | $5.36 | +86.57% | 1 | Mar 9, 2026 | |
| ARVN Arvinas | Maintains: Outperform | $14 → $19 | $10.29 | +84.65% | 1 | Feb 25, 2026 | |
| AURA Aura Biosciences | Reinstates: Outperform | $13 | $6.96 | +86.78% | 1 | Nov 26, 2025 | |
| NTLA Intellia Therapeutics | Downgrades: In-Line | $17 → $8 | $13.04 | -38.65% | 1 | Nov 11, 2025 | |
| PROK ProKidney | Initiates: Outperform | n/a | $1.86 | - | 1 | Sep 2, 2022 | |
| TRDA Entrada Therapeutics | Initiates: Outperform | n/a | $12.96 | - | 1 | Nov 24, 2021 | |
| STTK Shattuck Labs | Initiates: Outperform | n/a | $7.72 | - | 1 | Jan 11, 2021 | |
| NBTX Nanobiotix | Initiates: Outperform | n/a | $32.83 | - | 1 | Jan 6, 2021 |
Zymeworks
Mar 9, 2026
Maintains: Outperform
Price Target: $33 → $48
Current: $28.56
Upside: +68.07%
Caribou Biosciences
Mar 9, 2026
Maintains: Outperform
Price Target: $11 → $13
Current: $2.13
Upside: +510.33%
Atea Pharmaceuticals
Mar 9, 2026
Maintains: Outperform
Price Target: $6 → $10
Current: $5.36
Upside: +86.57%
Arvinas
Feb 25, 2026
Maintains: Outperform
Price Target: $14 → $19
Current: $10.29
Upside: +84.65%
Aura Biosciences
Nov 26, 2025
Reinstates: Outperform
Price Target: $13
Current: $6.96
Upside: +86.78%
Intellia Therapeutics
Nov 11, 2025
Downgrades: In-Line
Price Target: $17 → $8
Current: $13.04
Upside: -38.65%
ProKidney
Sep 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $1.86
Upside: -
Entrada Therapeutics
Nov 24, 2021
Initiates: Outperform
Price Target: n/a
Current: $12.96
Upside: -
Shattuck Labs
Jan 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.72
Upside: -
Nanobiotix
Jan 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $32.83
Upside: -